1 Department of Liver Surgery and Liver Transplantation, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China 2 Shanghai Engineering Research Center of Transplantation ...

The approval targets patients who have undergone a minimum of three previous therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cluster of differentiation 38 (CD38) ...

If approved, it will be prescribed to patients who have failed at least three lines of treatment, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.

Long-lived IgG-producing plasma cells can be targeted by means of their expression of CD38. Alternatively, B cells can be deprived of the B-cell activating factor required for their survival ...

"Anti-GPRC5D CAR T-cell therapy showed superior efficacy over CD38 antibody-based, carfilzomib [Kyprolis]-based, and selinexor [Xpovio]-based therapies in the study. Early initiation of anti ...